MSLN and neoplasm: ADXS-NEO is an interesting derivate of the L. monocytogenes-based cancer vaccines in that it is engineered to express patient-specific tumor antigens.102 CRS-207 is L. monocytogenes that expresses mesothelin, a tumor-associated antigen associated with malignant pleural mesothelioma and pancreatic cancer.